Bendamustine HCL for the treatment of relapsed indolent non-Hodgkin’s lymphoma

References

• AngerGHessePKöhlerP1967Erste klinische Erfahrungen mit einem neuen ZytostatikumDeutsch Gesundheitswes22107984
   PubMedGoogle Scholar
• AngerGHessePBaufeldH1969Behandlung des multiplen Myeloms mit einem neuen ZytostatikumDtsch Med Wochenschr4824955004903552
   PubMed Web of Science ®Google Scholar
• AngerGFinkRFleischerJ1975Vergleichsuntersuchungen zwischen Cytostasan und Cyclophosphamid bei der chronischen Lymphadenose, dem Plasmozytom, der Lymphogranulomatose und dem BronchialkarzinomDeutsch Gesundheitswes3012805
   Google Scholar
• ArmitageJ1993Treatment of non-Hodgkin’s lymphomaN Engl J Med3281023308450856
   PubMed Web of Science ®Google Scholar
• BlumenstengelKFrickeHJKathR1998Bendamustine (B), vincristine (O), prednisone (P) in relapsed and refractory low grade non-Hodgkin’s lymphoma (NHL) [abstract]Ann Hematol77Suppl 11S149
   PubMedGoogle Scholar
• BremerK2002High rates of long lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin’s lymphomasJ Cancer Res Clin Oncol128603912458340
   PubMed Web of Science ®Google Scholar
• BrockmannB1992Therapy of the recurrence of malignant lymphomaZ Aerztl Fortbild (Jena)86843
   PubMedGoogle Scholar
• ChowKUBoehrerSGeduldigK2001In vitro studies of apoptosis of neoplastic cells in low-grade non-Hodgkin’s lymphomas using combinations of established cytotoxic drugs with bendamustineHaematologica864859311410411
   PubMed Web of Science ®Google Scholar
• ChowKUSommerladWDBoehrerS2002Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspasesHaematologica87334311801463
   PubMed Web of Science ®Google Scholar
• FriedbergJWCohenPChenL2008Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin’s lymphoma: results from a phase II multicenter, single agent studyJ Clin Oncol262041018182663
   PubMed Web of Science ®Google Scholar
• HaaseDPreissRSohrR1990Untersuchungen zur Plasmaei-weißbindung von Bendamustin (Cytostasan) und AmbazoneZ Klin Med45126771
   Google Scholar
• HartmannMZimmerCH1972Investigation of cross-link formation in DNA by the alkylating cytostatica IMET 3106, 3393 and 3943Biochim Biophys Acta28738694629776
   PubMed Web of Science ®Google Scholar
• HeckHKPreissJMSchmidtP1998Bendamustine (B) and mitoxantrone (M) in the treatment of low grade non-Hodgkin’s lymphoma (NHL) [abstract]J Cancer Res Clin Oncol124SupplR147
   Google Scholar
• HeiderANiederleN2001Efficacy and toxicity of bendamustine in patients with relapsed low – grade non-Hodgkin’s lymphomasAnticancer Drugs12725911593053
   PubMed Web of Science ®Google Scholar
• HeroldMKeinertKAngerG1992Risk-adapted combined radio-therapy and chemotherapy for Hodgkin’s disease – results of a pilot studyOnkologie155015
   Google Scholar
• HeroldMSchulzeAMantovaniL1999BOP versus COP in advanced low-grade non-Hodgkin’s lymphoma – results of a randomized multicenter trial [abstract]Ann Oncol10Suppl 312510076735
   PubMed Web of Science ®Google Scholar
• HeroldMSchulzeANiederwieserD2006Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin’s lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19)J Cancer Res Clin Oncol1321051216088404
   PubMed Web of Science ®Google Scholar
• HesseGSchulzeWWachtelE1981Zur Methodik der Bestimmung alkylierender Aktivitäten von N-Losten mit Nitrobezylpyridin (NBP) in biologischem MaterialPharmazie36609127301901
   PubMed Web of Science ®Google Scholar
• KahlCHeroldMHöffkesH1997Bendamustine, methotrexate, mitoxantrone and prednisone (BMMP) for the treatment of high grade non-Hodgkin’s lymphomaOnkologie204068
   Web of Science ®Google Scholar
• KahlBBartlettNLLeonardJP2007Bendamustine is safe and effective in patients with rituximab-refractory, indolent B-cell non-Hodgkin’s lymphoma [abstract]Blood1101351
   Web of Science ®Google Scholar
• KathRHöffkenKMerkleK2000Prevention of immunological complications in bendamustine treatment [abstract]Onkologie23171
   Google Scholar
• KirchnerHHGaedeBSteinhauerEU2001Chemoimmuno-therapy with Fludarabine, Bendamustine and Rituximab for relapsed low grade malignant non-Hodgkin’s lymphoma [abstract]Blood98568
   Web of Science ®Google Scholar
• KönigUJunghassCDeckerS1999Response of refractory and relapsed low grade non-Hodgkin’s lymphoma and chronic lymphocytic leukemia to Dexa-BID, a bendamustine hydrochloride-containing regimen [abstract]Ann Oncol10Suppl 3132
   Google Scholar
• KönigsmannMKnaufWHeroldM2004Fludarabine and bendamustine in refractory and relapsed indolent lymphoma – a multicenter phase I/II trial of the east german society of hematology and oncology (OSHO)Leuk Lymphoma451821715223642
   PubMed Web of Science ®Google Scholar
• LeoniLMBaileyBReifertJ2008Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agentsClin Cancer Res143091718172283
   PubMed Web of Science ®Google Scholar
• MatthiasMPreissRSohrR1995Pharmacokinetics of bendamustine in patients with malignant tumors [abstract]Proc Am Soc Clin Oncol141476
   Google Scholar
• OzegowskiWKrebsD1963w-[bis-(chlorethyl)-amino-benzimidazolyl-(2)]-propionic or butyric acids as potential cytostatic agentsJ Prakt Chem2017886
   Google Scholar
• OzegowskiWKrebsD1971IMET 3393, gamma-(1-methyl-5-bis-(ß-chloräthyl)-amino-benzimidazolyl(2)-buttersäure-hydrochlorid, ein neues Zytostatikum aus der Reihe der Benzimidazol-LosteZbl Pharm110101319
   Google Scholar
• PreissRSohrRMatthiasM1985The pharmacokinetics of bendamustine (Cytostasan) in humansPharmazie4078244095129
   PubMed Web of Science ®Google Scholar
• RobinsonKSWilliamsMECohenP2005Bendamustine HCl (TREANDATM) treatment in combination with rituximab results in objective responses in patients with refractory/relapsed indolent B-cell and mantle cell non-Hodgkin’s lymphoma: Results from phase II multicenter study (SDX-105–02) [abstract]Blood106923
   Web of Science ®Google Scholar
• RuffertKJannHSyrbeG1989Cytostasan (bendamustine) as an alternative therapeutic approach to treat malignant non-Hodgkin’s lymphomaZ Klin Med446714
   Google Scholar
• RuffertK1999Therapy of low grade non-Hodgkin’s lymphoma (NHL) with bendamustine and oral etoposide [abstract]Ann Oncol10Suppl 312510076735
   PubMed Web of Science ®Google Scholar
• RummelMJChowKUHölzerD2002In vitro studies with bendamustine: enhanced activity in combination with rituximabSemin Oncol294 Suppl 13121412170426
   PubMed Web of Science ®Google Scholar
• RummelMJAl-BatranSEKimSZ2005Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low – grade non Hodgkin’s lymphomaJ Clin Oncol233383915908650
   PubMed Web of Science ®Google Scholar
• RummelMJvon GrünhagenUNiederleN2007Bendamustine plus rituximab versus CHOP plus rituximab in the first line treatment of patients with indolent and mantle cell lymphomas – first interim results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany) [abstract]Blood110385
   Google Scholar
• SchnabelRJungstandWGutscheW1967Comparative studies on the cystostatic activity of the new nitrogen mustard derivative IMET 3393 and endoxan in three experimental mouse tumours (Ehrlich-ascites-carcinoma, sarcoma 180 solid, leukaemia LAJ 1)Acta Biol Med1953458
   Google Scholar
• SchwänenCHeckerTHübingerG2002In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemiaLeukemia16209610512357363
   PubMed Web of Science ®Google Scholar
• StaibPSchinkotheTDimskiT1999In vitro modulation of ara-CTP accumulation in fresh AML cells by bendamustine in comparison with fludarabine, 2-CDA and gemcitabine [abstract]Blood9463
   Web of Science ®Google Scholar
• StrumbergDHarstrickADollK1996Bendamustine hydrochloride activity against doxorubicine-resistant human breast cancer cell linesAnticancer Drugs7415218826610
   PubMed Web of Science ®Google Scholar
• Van der JagtRHCohenPChesonBD2006Phase II Results of bendamustine in combination with rituximab in relapsed indolent and mantle-cell non-Hodgkin’s lymphoma [abstract]Blood1082710
   Web of Science ®Google Scholar
• WeideRHeymannsJKöpplerH1999Successful treatment of alkylating agent resistant low grade B-cell non Hodgkin’s lymphomas with bendamustine/mitoxantrone/rituximab (BMR) [abstract]Onkologie22Suppl 1644
   Google Scholar
• WeideRHeymannsJGoresA2002Bendamustine, mitoxantrone and rituximab (BMR): A new effective regimen for refractory or relapsed indolent lymphomasLeuk Lymphoma433273111999564
   PubMed Web of Science ®Google Scholar
• WeideRPandorfAHeymannsJ2004Bendamustine/Mitoxantrone/ Rituximab (BMR): A very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot studyLeuk Lymphoma452445244915621757
   PubMed Web of Science ®Google Scholar
• WeideRHessGKöpplerH2007High anti – lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A mul-ticenter phase II study of the German Low Grade Lymphoma Study Group (GLSG)Leuk Lymphoma48129930617613757
   PubMed Web of Science ®Google Scholar